Epigenetic epidemiology of cancer

Biochemical and Biophysical Research Communications

Volumn 455, Issue 1-2, 2014, Pages 70-83

  Barrow, Timothy M ^a,b,c   Michels, Karin B ^a,d,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b German Consortium for Translational Cancer Research (DKTK)   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Cancer; DNA methylation; Epidemiology; Epigenetics

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; HISTONE H3; K RAS PROTEIN; LINE 1 PROTEIN; METHYL CPG BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 143; MICRORNA 155; MICRORNA 21; MICRORNA 210; MICRORNA 372; OXALIPLATIN; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SOMATOMEDIN B; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR GATA 5; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; EPIGENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG CANCER; REVIEW; BLADDER TUMOR; BLOOD; BREAST TUMOR; COLORECTAL TUMOR; EPIDEMIOLOGY; FEMALE; GENETIC ASSOCIATION; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; NEOPLASMS; RISK FACTOR;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; EPIDEMIOLOGIC RESEARCH DESIGN; EPIGENESIS, GENETIC; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84912059273     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.002     Document Type: Review

References (161)

1. A. Benard, C.J. van de Velde, L. Lessard, H. Putter, L. Takeshima, P.J. Kuppen, and D.S. Hoon Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer Br. J. Cancer 109 2013 3073 3083
2. E. Ko, B.B. Lee, Y. Kim, E.J. Lee, E.Y. Cho, J. Han, Y.M. Shim, J. Park, and D.H. Kim Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer Clin. Cancer Res. 19 2013 1204 1212
3. K.H. Lee, J.S. Lee, J.H. Nam, C. Choi, M.C. Lee, C.S. Park, S.W. Juhng, and J.H. Lee Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence Langenbecks Arch. Surg. 396 2011 1017 1026
4. U. Lim, A. Flood, S.W. Choi, D. Albanes, A.J. Cross, A. Schatzkin, R. Sinha, H.A. Katki, B. Cash, P. Schoenfeld, and R. Stolzenberg-Solomon Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women Gastroenterology 134 2008 47 55
5. E. Nadal, G. Chen, M. Gallegos, L. Lin, D. Ferrer-Torres, A. Truini, Z. Wang, J. Lin, R.M. Reddy, R. Llatjos, I. Escobar, J. Moya, A.C. Chang, F. Cardenal, G. Capellà, and D.G. Beer Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma Clin. Cancer Res. 19 2013 6842 6852
6. G. Nikolaidis, O.Y. Raji, S. Markopoulou, J.R. Gosney, J. Bryan, C. Warburton, M. Walshaw, J. Sheard, J.K. Field, and T. Liloglou DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer Cancer Res. 72 2012 5692 5701
7. J. Sandoval, J. Mendez-Gonzalez, E. Nadal, G. Chen, F.J. Carmona, S. Sayols, S. Moran, H. Heyn, M. Vizoso, A. Gomez, M. Sanchez-Cespedes, Y. Assenov, F. Müller, C. Bock, M. Taron, J. Mora, L.A. Muscarella, T. Liloglou, M. Davies, M. Pollan, M.J. Pajares, W. Torre, L.M. Montuenga, E. Brambilla, J.K. Field, L. Roz, M. LoIacono, G.V. Scagliotti, R. Rosell, D.G. Beer, and M. Esteller A prognostic DNA methylation signature for stage I non-small-cell lung cancer J. Clin. Oncol. 31 2013 4140 4147
8. A.E. Teschendorff, A. Jones, H. Fiegl, A. Sargent, J.J. Zhuang, H.C. Kitchener, and M. Widschwendter Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation Genome Med. 4 2012 24
9. C.J. Marsit, M.R. Karagas, H. Danaee, M. Liu, A. Andrew, A. Schned, H.H. Nelson, and K.T. Kelsey Carcinogen exposure and gene promoter hypermethylation in bladder cancer Carcinogenesis 27 2006 112 116
10. A. Avraham, R. Uhlmann, A. Shperber, M. Birnbaum, J. Sandbank, A. Sella, S. Sukumar, and E. Evron Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients Int. J. Cancer 131 2012 E1166 E1172
11. A. Buhmeida, A. Merdad, J. Al-Maghrabi, J. El-Maghrabi, F. Al-Thobaiti, M. Ata, A. Bugis, K. Syrjänen, A. Abuzenadah, A. Chaudhary, M. Gari, M. Al-Qahtani, and A. Dallol RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency Anticancer Res. 31 2011 2975 2981
12. Y.H. Cho, J. Shen, M.D. Gammon, Y.J. Zhang, Q. Wang, K. Gonzalez, X. Xu, P.T. Bradshaw, S.L. Teitelbaum, G. Garbowski, H. Hibshoosh, A.I. Neugut, J. Chen, and R.M. Santella Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients Breast Cancer Res. Treat. 131 2012 197 205
13. M.A. Alvi, X. Liu, M. O'Donovan, R. Newton, L. Wernisch, N.B. Shannon, K. Shariff, M. di Pietro, J.J. Bergman, K. Ragunath, and R.C. Fitzgerald DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus Clin. Cancer Res. 19 2013 878 888
14. S.A. Belinsky, K.C. Liechty, F.D. Gentry, H.J. Wolf, J. Rogers, K. Vu, J. Haney, T.C. Kennedy, F.R. Hirsch, Y. Miller, W.A. Franklin, J.G. Herman, S.B. Baylin, P.A. Bunn, and T. Byers Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort Cancer Res. 66 2006 3338 3344
15. K.D. Hansen, W. Timp, H.C. Bravo, S. Sabunciyan, B. Langmead, O.G. McDonald, B. Wen, H. Wu, Y. Liu, D. Diep, E. Briem, K. Zhang, R.A. Irizarry, and A.P. Feinberg Increased methylation variation in epigenetic domains across cancer types Nat. Genet. 43 2011 768 775
16. A.S. Yang, M.R. Estécio, K. Doshi, Y. Kondo, E.H. Tajara, and J.P. Issa A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements Nucleic Acids Res. 32 2004 e38
17. M. Karimi, S. Johansson, D. Stach, M. Corcoran, D. Grandér, M. Schalling, G. Bakalkin, F. Lyko, C. Larsson, and T.J. Ekström LUMA (LUminometric Methylation Assay) - a high throughput method to the analysis of genomic DNA methylation Exp. Cell Res. 312 2006 1989 1995
18. H.C. Wu, L. Delgado-Cruzata, J.D. Flom, M. Kappil, J.S. Ferris, Y. Liao, R.M. Santella, and M.B. Terry Global methylation profiles in DNA from different blood cell types Epigenetics 6 2011 76 85
19. X. Xu, M.D. Gammon, H. Hernandez-Vargas, Z. Herceg, J.G. Wetmur, S.L. Teitelbaum, P.T. Bradshaw, A.I. Neugut, R.M. Santella, and J. Chen DNA methylation in peripheral blood measured by LUMA is associated with breast cancer in a population-based study FASEB J. 26 2012 2657 2666
20. S. Lisanti, W.A. Omar, B. Tomaszewski, S. De Prins, G. Jacobs, G. Koppen, J.C. Mathers, and S.A. Langie Comparison of methods for quantification of global DNA methylation in human cells and tissues PLoS ONE 8 2013 e79044
21. H.C. Wu, Q. Wang, L. Delgado-Cruzata, R.M. Santella, and M.B. Terry Genomic methylation changes over time in peripheral blood mononuclear cell DNA: differences by assay type and baseline values Cancer Epidemiol. Biomarkers Prev. 21 2012 1314 1318
22. D.J. Weisenberger, M. Campan, T.I. Long, M. Kim, C. Woods, E. Fiala, M. Ehrlich, and P.W. Laird Analysis of repetitive element DNA methylation by MethyLight Nucleic Acids Res. 33 2005 6823 6836
23. K.B. Michels, A.M. Binder, S. Dedeurwaerder, C.B. Epstein, J.M. Greally, I. Gut, E.A. Houseman, B. Izzi, K.T. Kelsey, A. Meissner, A. Milosavljevic, K.D. Siegmund, C. Bock, and R.A. Irizarry Recommendations for the design and analysis of epigenome-wide association studies Nat. Methods 10 2013 949 955
24. P. Boyle, K. Clement, H. Gu, Z.D. Smith, M. Ziller, J.L. Fostel, L. Holmes, J. Meldrim, F. Kelley, A. Gnirke, and A. Meissner Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling Genome Biol. 13 2012 R92
25. 6-methylguanine-DNA methyltransferase) gene promoter in sporadic colorectal cancer DNA Cell Biol. 32 2013 371 377
26. S. Bhusari, B. Yang, J. Kueck, W. Huang, and D.F. Jarrard Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer Prostate 71 2011 1621 1630
27. E.M. Wolff, Y. Chihara, F. Pan, D.J. Weisenberger, K.D. Siegmund, K. Sugano, K. Kawashima, P.W. Laird, P.A. Jones, and G. Liang Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue Cancer Res. 70 2010 8169 8178
28. K. Nosho, S. Kure, N. Irahara, K. Shima, Y. Baba, D. Spiegelman, J.A. Meyerhardt, E.L. Giovannucci, C.S. Fuchs, and S. Ogino A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers Gastroenterology 137 2009 1609-20.e1-3
29. C. Gu, J. Lu, T. Cui, C. Lu, H. Shi, W. Xu, X. Yuan, X. Yang, Y. Huang, and M. Lu Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis PLoS ONE 8 2013 e72633
30. L. Barault, R.E. Ellsworth, H.R. Harris, A.L. Valente, C.D. Shriver, and K.B. Michels Leukocyte DNA as surrogate for the evaluation of imprinted Loci methylation in mammary tissue DNA PLoS ONE 8 2013 e55896
31. Y. Ito, T. Koessler, A.E. Ibrahim, S. Rai, S.L. Vowler, S. Abu-Amero, A.L. Silva, A.T. Maia, J.E. Huddleston, S. Uribe-Lewis, K. Woodfine, M. Jagodic, R. Nativio, A. Dunning, G. Moore, E. Klenova, S. Bingham, P.D. Pharoah, J.D. Brenton, S. Beck, M.S. Sandhu, and A. Murrell Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer Hum. Mol. Genet. 17 2008 2633 2643
32. H. Cui, M. Cruz-Correa, F.M. Giardiello, D.F. Hutcheon, D.R. Kafonek, S. Brandenburg, Y. Wu, X. He, N.R. Powe, and A.P. Feinberg Loss of IGF2 imprinting: a potential marker of colorectal cancer risk Science 299 2003 1753 1755
33. E.A. Houseman, W.P. Accomando, D.C. Koestler, B.C. Christensen, C.J. Marsit, H.H. Nelson, J.K. Wiencke, and K.T. Kelsey DNA methylation arrays as surrogate measures of cell mixture distribution BMC Bioinformatics 13 2012 86
34. D.C. Koestler, C.J. Marsit, B.C. Christensen, W. Accomando, S.M. Langevin, E.A. Houseman, H.H. Nelson, M.R. Karagas, J.K. Wiencke, and K.T. Kelsey Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers Cancer Epidemiol. Biomarkers Prev. 21 2012 1293 1302
35. R. Grützmann, B. Molnar, C. Pilarsky, J.K. Habermann, P.M. Schlag, H.D. Saeger, S. Miehlke, T. Stolz, F. Model, U.J. Roblick, H.P. Bruch, R. Koch, V. Liebenberg, T. Devos, X. Song, R.H. Day, A.Z. Sledziewski, and C. Lofton-Day Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay PLoS ONE 3 2008 e3759
36. R.H. Carvalho, V. Haberle, J. Hou, T. van Gent, S. Thongjuea, W. van Ijcken, C. Kockx, R. Brouwer, E. Rijkers, A. Sieuwerts, J. Foekens, M. van Vroonhoven, J. Aerts, F. Grosveld, B. Lenhard, and S. Philipsen Genome-wide DNA methylation profiling of non-small cell lung carcinomas Epigenetics Chromatin 5 2012 9
37. D. Connolly, Z. Yang, M. Castaldi, N. Simmons, M.H. Oktay, S. Coniglio, M.J. Fazzari, P. Verdier-Pinard, and C. Montagna Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression Breast Cancer Res. 13 2011 R76
38. S.M. Tajuddin, A.F. Amaral, A.F. Fernández, S. Rodríguez-Rodero, R.M. Rodríguez, L.E. Moore, A. Tardón, A. Carrato, M. García-Closas, D.T. Silverman, B.P. Jackson, R. García-Closas, A.L. Cook, K.P. Cantor, S. Chanock, M. Kogevinas, N. Rothman, F.X. Real, M.F. Fraga, and N. Malats Spanish bladder cancer/EPICURO study investigators, genetic and non-genetic predictors of LINE-1 methylation in leukocyte DNA Environ. Health Perspect. 121 2013 650 656
39. M. Widschwendter, S. Apostolidou, E. Raum, D. Rothenbacher, H. Fiegl, U. Menon, C. Stegmaier, I.J. Jacobs, and H. Brenner Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study PLoS ONE 3 2008 e2656
40. M. Li, W.D. Chen, N. Papadopoulos, S.N. Goodman, N.C. Bjerregaard, S. Laurberg, B. Levin, H. Juhl, N. Arber, H. Moinova, K. Durkee, K. Schmidt, Y. He, F. Diehl, V.E. Velculescu, S. Zhou, L.A. Diaz, K.W. Kinzler, S.D. Markowitz, and B. Vogelstein Sensitive digital quantification of DNA methylation in clinical samples Nat. Biotechnol. 27 2009 858 863
41. K.C. Chan, P. Jiang, C.W. Chan, K. Sun, J. Wong, E.P. Hui, S.L. Chan, W.C. Chan, D.S. Hui, S.S. Ng, H.L. Chan, C.S. Wong, B.B. Ma, A.T. Chan, P.B. Lai, H. Sun, R.W. Chiu, and Y.M. Lo Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing Proc. Natl. Acad. Sci. U.S.A. 110 2013 18761 18768
42. U. Gezer, D. Ustek, E.E. Yörüker, A. Cakiris, N. Abaci, G. Leszinski, N. Dalay, and S. Holdenrieder Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer Tumour Biol. 34 2013 329 336
43. T. Benaglia, L.D. Sharples, R.C. Fitzgerald, and G. Lyratzopoulos Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus Gastroenterology 144 2013 62-73.e6
44. S.R. Kadri, P. Lao-Sirieix, M. O'Donovan, I. Debiram, M. Das, J.M. Blazeby, J. Emery, A. Boussioutas, H. Morris, F.M. Walter, P. Pharoah, R.H. Hardwick, and R.C. Fitzgerald Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study BMJ 341 2010 c4372
45. W.J. Bulsiewicz, H.P. Kim, E.S. Dellon, C.C. Cotton, S. Pasricha, R.D. Madanick, M.B. Spacek, S.E. Bream, X. Chen, R.C. Orlando, and N.J. Shaheen Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus Clin. Gastroenterol. Hepatol. 11 2013 636 642
46. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
47. V. Psofaki, C. Kalogera, N. Tzambouras, D. Stephanou, E. Tsianos, K. Seferiadis, and G. Kolios Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas World J. Gastroenterol. 16 2010 3553 3560
48. X. Li, X. Yao, Y. Wang, F. Hu, F. Wang, L. Jiang, Y. Liu, D. Wang, G. Sun, and Y. Zhao MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features PLoS ONE 8 2013 e59064
49. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin, and J.P. Issa CpG island methylator phenotype in colorectal cancer Proc. Natl. Acad. Sci. U.S.A. 96 1999 8681 8686
50. Y. Baba, C. Huttenhower, K. Nosho, N. Tanaka, K. Shima, A. Hazra, E.S. Schernhammer, D.J. Hunter, E.L. Giovannucci, C.S. Fuchs, and S. Ogino Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors Mol. Cancer 9 2010 125
51. L.J. Gay, P.N. Mitrou, J. Keen, R. Bowman, A. Naguib, J. Cooke, G.G. Kuhnle, P.A. Burns, R. Luben, M. Lentjes, K.T. Khaw, R.Y. Ball, A.E. Ibrahim, and M.J. Arends Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study J. Pathol. 228 2012 405 415
52. R. Nishihara, T. Morikawa, A. Kuchiba, P. Lochhead, M. Yamauchi, X. Liao, Y. Imamura, K. Nosho, K. Shima, I. Kawachi, Z.R. Qian, C.S. Fuchs, A.T. Chan, E. Giovannucci, and S. Ogino A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification Am. J. Epidemiol. 178 2013 84 100
53. M. Pufulete, R. Al-Ghnaniem, A.J. Leather, P. Appleby, S. Gout, C. Terry, P.W. Emery, and T.A. Sanders Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study Gastroenterology 124 2003 1240 1248
54. E.S. Schernhammer, E. Giovannucci, T. Kawasaki, B. Rosner, C.S. Fuchs, and S. Ogino Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer Gut 59 2010 794 799
55. W.Y. Huang, L.J. Su, R.B. Hayes, L.E. Moore, H.A. Katki, S.I. Berndt, J.L. Weissfeld, S. Yegnasubramanian, and M.P. Purdue Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk Cancer Epidemiol. Biomarkers Prev. 21 2012 2014 2021
56. E.S. Schernhammer, E. Giovannucci, Y. Baba, C.S. Fuchs, and S. Ogino B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP) PLoS ONE 6 2011 e21102
57. B. Van Guelpen, A.M. Dahlin, J. Hultdin, V. Eklöf, I. Johansson, M.L. Henriksson, I. Cullman, G. Hallmans, and R. Palmqvist One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study Cancer Causes Control 21 2010 557 566
58. S. Ogino, R. Nishihara, P. Lochhead, Y. Imamura, A. Kuchiba, T. Morikawa, M. Yamauchi, X. Liao, Z.R. Qian, R. Sun, K. Sato, G.J. Kirkner, M. Wang, D. Spiegelman, J.A. Meyerhardt, E.S. Schernhammer, A.T. Chan, E. Giovannucci, and C.S. Fuchs Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level J. Natl Cancer Inst. 105 2013 130 140
59. A.S. Fleisher, M. Esteller, N. Harpaz, A. Leytin, A. Rashid, Y. Xu, J. Liang, O.C. Stine, J. Yin, T.T. Zou, J.M. Abraham, D. Kong, K.T. Wilson, S.P. James, J.G. Herman, and S.J. Meltzer Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1 Cancer Res. 60 2000 4864 4868
60. M. Svrcek, J. El-Bchiri, A. Chalastanis, E. Capel, S. Dumont, O. Buhard, C. Oliveira, R. Seruca, C. Bossard, J.F. Mosnier, F. Berger, E. Leteurtre, A. Lavergne-Slove, M.P. Chenard, R. Hamelin, J. Cosnes, L. Beaugerie, E. Tiret, A. Duval, and J.F. Fléjou Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability J. Clin. Oncol. 25 2007 4231 4238
61. L. Tarmin, J. Yin, N. Harpaz, M. Kozam, J. Noordzij, L.B. Antonio, H.Y. Jiang, O. Chan, K. Cymes, and S.J. Meltzer Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms Cancer Res. 55 1995 2035 2038
62. E.H. van Roon, N.F. de Miranda, M.P. van Nieuwenhuizen, E.J. de Meijer, M. van Puijenbroek, P.S. Yan, T.H. Huang, T. van Wezel, H. Morreau, and J.M. Boer Tumour-specific methylation of PTPRG intron 1 locus in sporadic and Lynch syndrome colorectal cancer Eur. J. Hum. Genet. 19 2011 307 312
63. M.R. Kohonen-Corish, J. Tseung, C. Chan, N. Currey, O.F. Dent, S. Clarke, L. Bokey, and P.H. Chapuis KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer Int. J. Cancer 134 2014 2820 2828
64. A. Naguib, P.N. Mitrou, L.J. Gay, J.C. Cooke, R.N. Luben, R.Y. Ball, A. McTaggart, M.J. Arends, and S.A. Rodwell Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study BMC Cancer 10 2010 99
65. H. Rajagopalan, A. Bardelli, C. Lengauer, K.W. Kinzler, B. Vogelstein, and V.E. Velculescu Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 418 2002 934
66. J.C. Kim, J.S. Choi, S.A. Roh, D.H. Cho, T.W. Kim, and Y.S. Kim Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas Ann. Surg. Oncol. 17 2010 1767 1776
67. H. Nan, E.L. Giovannucci, K. Wu, J. Selhub, L. Paul, B. Rosner, C.S. Fuchs, and E. Cho Pre-diagnostic leukocyte genomic DNA methylation and the risk of colorectal cancer in women PLoS ONE 8 2013 e59455
68. T.R. Church, M. Wandell, C. Lofton-Day, S.J. Mongin, M. Burger, S.R. Payne, E. Castaños-Vélez, B.A. Blumenstein, T. Rösch, N. Osborn, D. Snover, R.W. Day, and D.F. Ransohoff PRESEPT Clinical Study Steering Committee, Investigators and Study Team, Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer Gut 63 2014 317 325
69. R. Kaaks, P. Stattin, S. Villar, A.R. Poetsch, L. Dossus, A. Nieters, E. Riboli, R. Palmqvist, G. Hallmans, C. Plass, and M.D. Friesen Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort Cancer Res. 69 2009 5400 5405
70. C.P. Lange, M. Campan, T. Hinoue, R.F. Schmitz, A.E. van der Meulen-de Jong, H. Slingerland, P.J. Kok, C.M. van Dijk, D.J. Weisenberger, H. Shen, R.A. Tollenaar, and P.W. Laird Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer PLoS ONE 7 2012 e50266
71. J.B. Kisiel, T.C. Yab, F.T. Nazer Hussain, W.R. Taylor, M.M. Garrity-Park, W.J. Sandborn, E.V. Loftus, B.G. Wolff, T.C. Smyrk, S.H. Itzkowitz, D.T. Rubin, H. Zou, D.W. Mahoney, and D.A. Ahlquist Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease Aliment Pharmacol. Ther. 37 2013 546 554
72. T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, T.R. Levin, P. Lavin, G.P. Lidgard, D.A. Ahlquist, and B.M. Berger Multitarget stool DNA testing for colorectal-cancer screening N. Engl. J. Med. 370 2014 1287 1297
73. C. Guastadisegni, M. Colafranceschi, L. Ottini, and E. Dogliotti Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data Eur. J. Cancer 46 2010 2788 2798
74. K. Nosho, N. Irahara, K. Shima, S. Kure, G.J. Kirkner, E.S. Schernhammer, A. Hazra, D.J. Hunter, J. Quackenbush, D. Spiegelman, E.L. Giovannucci, C.S. Fuchs, and S. Ogino Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample PLoS ONE 3 2008 e3698
75. S. Ogino, K. Nosho, G.J. Kirkner, T. Kawasaki, J.A. Meyerhardt, M. Loda, E.L. Giovannucci, and C.S. Fuchs CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut 58 2009 90 96
76. S.W. Han, H.J. Lee, J.M. Bae, N.Y. Cho, K.H. Lee, T.Y. Kim, D.Y. Oh, S.A. Im, Y.J. Bang, S.Y. Jeong, K.J. Park, J.G. Park, G.H. Kang, and T.Y. Kim Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer Int. J. Cancer 132 2013 2209 2216
77. S. Ogino, K. Nosho, G.J. Kirkner, T. Kawasaki, A.T. Chan, E.S. Schernhammer, E.L. Giovannucci, and C.S. Fuchs A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer J. Natl Cancer Inst. 100 2008 1734 1738
78. K. Shima, K. Nosho, Y. Baba, M. Cantor, J.A. Meyerhardt, E.L. Giovannucci, C.S. Fuchs, and S. Ogino Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review Int. J. Cancer 128 2011 1080 1094
79. S. Veganzones-de-Castro, S. Rafael-Fernández, M. Vidaurreta-Lázaro, V. de-la-Orden, B. Mediero-Valeros, C. Fernández, and M.L. Maestro-de las Casas p16 gene methylation in colorectal cancer patients with long-term follow-up Rev. Esp. Enferm. Dig. 104 2012 111 117
80. H. Mitomi, N. Fukui, N. Tanaka, H. Kanazawa, T. Saito, T. Matsuoka, and T. Yao Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity J. Cancer Res. Clin. Oncol. 136 2010 323 331
81. K. Shima, T. Morikawa, Y. Baba, K. Nosho, M. Suzuki, M. Yamauchi, M. Hayashi, E. Giovannucci, C.S. Fuchs, and S. Ogino MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers Cancer Causes Control 22 2011 301 309
82. Y. Takahashi, T. Iwaya, G. Sawada, J. Kurashige, T. Matsumura, R. Uchi, H. Ueo, Y. Takano, H. Eguchi, T. Sudo, K. Sugimachi, H. Yamamoto, Y. Doki, M. Mori, and K. Mimori Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer Ann. Surg. Oncol. 21 2014 205 212
83. T. Hashimoto, M. Yamakawa, S. Kimura, O. Usuba, and M. Toyono Expression of acetylated and dimethylated histone H3 in colorectal cancer Dig. Surg. 30 2013 249 258
84. H. Tamagawa, T. Oshima, M. Numata, N. Yamamoto, M. Shiozawa, S. Morinaga, Y. Nakamura, M. Yoshihara, Y. Sakuma, Y. Kameda, M. Akaike, N. Yukawa, Y. Rino, M. Masuda, and Y. Miyagi Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer Eur. J. Surg. Oncol. 39 2013 655 661
85. M. Takawa, K. Masuda, M. Kunizaki, Y. Daigo, K. Takagi, Y. Iwai, H.S. Cho, G. Toyokawa, Y. Yamane, K. Maejima, H.I. Field, T. Kobayashi, T. Akasu, M. Sugiyama, E. Tsuchiya, Y. Atomi, B.A. Ponder, Y. Nakamura, and R. Hamamoto Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker Cancer Sci. 102 2011 1298 1305
86. J.M. Carethers, E. Smith, C.A. Behling, L. Nguyen, A. Tajima, R.T. Doctolero, B.L. Cabrera, A. Goel, C.A. Arnold, K. Miyai, and C. Boland Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer Gastroenterology 126 2004 394 401
87. C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, R. Gryfe, L.E. Shepherd, D. Tu, M. Redston, and S. Gallinger Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N. Engl. J. Med. 349 2003 247 257
88. A. Zaanan, J.F. Fléjou, J.F. Emile, G.G. Des, P. Cuilliere-Dartigues, D. Malka, C. Lecaille, P. Validire, C. Louvet, P. Rougier, A. de Gramont, F. Bonnetain, F. Praz, and J. Taïeb Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy Clin. Cancer Res. 17 2011 7470 7478
89. M.M. Bertagnolli, D. Niedzwiecki, C.C. Compton, H.P. Hahn, M. Hall, B. Damas, S.D. Jewell, R.J. Mayer, R.M. Goldberg, L.B. Saltz, R.S. Warren, and M. Redston Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 J. Clin. Oncol. 27 2009 1814 1821
90. K. Kawakami, A. Matsunoki, M. Kaneko, K. Saito, G. Watanabe, and T. Minamoto Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer Cancer Sci. 102 2011 166 174
91. C. Moutinho, A. Martinez-Cardús, C. Santos, V. Navarro-Pérez, E. Martínez-Balibrea, E. Musulen, F.J. Carmona, A. Sartore-Bianchi, A. Cassingena, S. Siena, E. Elez, J. Tabernero, R. Salazar, A. Abad, and M. Esteller Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer J. Natl. Cancer Inst. 106 2014 djt322
92. N.S. Shenker, S. Polidoro, K. van Veldhoven, C. Sacerdote, F. Ricceri, M.A. Birrell, M.G. Belvisi, R. Brown, P. Vineis, and J.M. Flanagan Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking Hum. Mol. Genet. 22 2013 843 851
93. N.S. Shenker, P.M. Ueland, S. Polidoro, K. van Veldhoven, F. Ricceri, R. Brown, J.M. Flanagan, and P. Vineis DNA methylation as a long-term biomarker of exposure to tobacco smoke Epidemiology 24 2013 712 716
94. B.R. Joubert, S.E. Håberg, R.M. Nilsen, X. Wang, S.E. Vollset, S.K. Murphy, Z. Huang, C. Hoyo, ∅. Midttun, L.A. Cupul-Uicab, P.M. Ueland, M.C. Wu, W. Nystad, D.A. Bell, S.D. Peddada, and S.J. London 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy Environ. Health Perspect. 120 2012 1425 1431
95. A. Baccarelli, R.O. Wright, V. Bollati, L. Tarantini, A.A. Litonjua, H.H. Suh, A. Zanobetti, D. Sparrow, P.S. Vokonas, and J. Schwartz Rapid DNA methylation changes after exposure to traffic particles Am. J. Respir. Crit. Care Med. 179 2009 572 578
96. L. Tarantini, M. Bonzini, P. Apostoli, V. Pegoraro, V. Bollati, B. Marinelli, L. Cantone, G. Rizzo, L. Hou, J. Schwartz, P.A. Bertazzi, and A. Baccarelli Effects of particulate matter on genomic DNA methylation content and iNOS promoter methylation Environ. Health Perspect. 117 2009 217 222
97. H.M. Byun, V. Motta, T. Panni, P.A. Bertazzi, P. Apostoli, L. Hou, and A.A. Baccarelli Evolutionary age of repetitive element subfamilies and sensitivity of DNA methylation to airborne pollutants Part. Fibre Toxicol. 10 2013 28
98. L. Hou, X. Zhang, Y. Zheng, S. Wang, C. Dou, L. Guo, H.M. Byun, V. Motta, J. McCracken, A. Díaz, C.M. Kang, P. Koutrakis, P.A. Bertazzi, J. Li, J. Schwartz, and A.A. Baccarelli Altered methylation in tandem repeat element and elemental component levels in inhalable air particles Environ. Mol. Mutagen. 55 2014 256 265
99. P. Vineis, S.-C. Chuang, T. Vaissière, C. Cuenin, F. Ricceri G. collaborators M. Johansson, P. Ueland, P. Brennan, and Z. Herceg DNA methylation changes associated with cancer risk factors and blood levels of vitamin metabolites in a prospective study Epigenetics 6 2011 195 201
100. R. Cirincione, C. Lintas, D. Conte, L. Mariani, L. Roz, A.M. Vignola, U. Pastorino, and G. Sozzi Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study Int. J. Cancer 118 2006 1248 1253
101. P. Ilse, S. Biesterfeld, N. Pomjanski, C. Fink, and M. Schramm SHOX2 DNA methylation is a tumour marker in pleural effusions Cancer Genomics Proteomics 10 2013 217 223
102. W.H. Roa, J.O. Kim, R. Razzak, H. Du, L. Guo, R. Singh, S. Gazala, S. Ghosh, E. Wong, A.A. Joy, J.Z. Xing, and E.L. Bedard Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer Clin. Invest. Med. 35 2012 E271
103. J. Shen, J. Liao, M.A. Guarnera, H. Fang, L. Cai, S.A. Stass, and F. Jiang Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis J. Thorac. Oncol. 9 2014 33 40
104. H.S. Hsu, T.P. Chen, C.K. Wen, C.H. Hung, C.Y. Chen, J.T. Chen, and Y.C. Wang Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment J. Pathol. 213 2007 412 419
105. S. Bruse, H. Petersen, J. Weissfeld, M. Picchi, R. Willink, K. Do, J. Siegfried, S.A. Belinsky, and Y. Tesfaigzi Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion Respir. Res. 15 2014 2
106. A.J. Hubers, D.A. Heideman, G.J. Herder, S.A. Burgers, P.J. Sterk, P.W. Kunst, H.J. Smit, P.E. Postmus, B.I. Witte, S. Duin, P.J. Snijders, E.F. Smit, and E. Thunnissen Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer J. Clin. Pathol. 65 2012 541 545
107. S. Leng, K. Do, C.M. Yingling, M.A. Picchi, H.J. Wolf, T.C. Kennedy, W.J. Feser, A.E. Baron, W.A. Franklin, M.V. Brock, J.G. Herman, S.B. Baylin, T. Byers, C.A. Stidley, and S.A. Belinsky Defining a gene promoter methylation signature in sputum for lung cancer risk assessment Clin. Cancer Res. 18 2012 3387 3395
108. S. Leng, Y. Liu, C.L. Thomas, W.J. Gauderman, M.A. Picchi, S.E. Bruse, X. Zhang, K.G. Flores, D. Van Den Berg, C.A. Stidley, F.D. Gilliland, and S.A. Belinsky Native American ancestry affects the risk for gene methylation in the lungs of Hispanic smokers from New Mexico Am. J. Respir. Crit. Care Med. 188 2013 1110 1116
109. Z. Lou-Qian, Y. Rong, L. Ming, Y. Xin, J. Feng, and X. Lin The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis PLoS ONE 8 2013 e54970
110. N.G. Bediaga, M.P. Davies, A. Acha-Sagredo, R. Hyde, O.Y. Raji, R. Page, M. Walshaw, J. Gosney, A. Alfirevic, J.K. Field, and T. Liloglou A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material Br. J. Cancer 109 2013 2404 2411
111. E. Duncavage, B. Goodgame, A. Sezhiyan, R. Govindan, and J. Pfeifer Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer J. Thorac. Oncol. 5 2010 1755 1763
112. M. Raponi, L. Dossey, T. Jatkoe, X. Wu, G. Chen, H. Fan, and D.G. Beer MicroRNA classifiers for predicting prognosis of squamous cell lung cancer Cancer Res. 69 2009 5776 5783
113. X.G. Liu, W.Y. Zhu, Y.Y. Huang, L.N. Ma, S.Q. Zhou, Y.K. Wang, F. Zeng, J.H. Zhou, and Y.K. Zhang High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer Med. Oncol. 29 2012 618 626
114. T. Berghmans, L. Ameye, L. Willems, M. Paesmans, C. Mascaux, J.J. Lafitte, A.P. Meert, A. Scherpereel, A.B. Cortot, I. Cstoth, T. Dernies, L. Toussaint, N. Leclercq, and J.P. Sculier European Lung Cancer Working Party, Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study Lung Cancer 82 2013 340 345
115. N.G. Bediaga, A. Acha-Sagredo, I. Guerra, A. Viguri, C. Albaina, I. Ruiz Diaz, R. Rezola, M.J. Alberdi, J. Dopazo, D. Montaner, M. Renobales, A.F. Fernández, J.K. Field, M.F. Fraga, T. Liloglou, and M.M. de Pancorbo DNA methylation epigenotypes in breast cancer molecular subtypes Breast Cancer Res. 12 2010 R77
116. M.J. Fackler, C.B. Umbricht, D. Williams, P. Argani, L.A. Cruz, V.F. Merino, W.W. Teo, Z. Zhang, P. Huang, K. Visvananthan, J. Marks, S. Ethier, J.W. Gray, A.C. Wolff, L.M. Cope, and S. Sukumar Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence Cancer Res. 71 2011 6195 6207
117. W. Feng, L. Shen, S. Wen, D.G. Rosen, J. Jelinek, X. Hu, S. Huan, M. Huang, J. Liu, A.A. Sahin, K.K. Hunt, R.C. Bast, Y. Shen, J.P. Issa, and Y. Yu Correlation between CpG methylation profiles and hormone receptor status in breast cancers Breast Cancer Res. 9 2007 R57
118. L. Li, K.M. Lee, W. Han, J.Y. Choi, J.Y. Lee, G.H. Kang, S.K. Park, D.Y. Noh, K.Y. Yoo, and D. Kang Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer Hum. Mol. Genet. 19 2010 4273 4277
119. K.P. Suijkerbuijk, M.J. Fackler, S. Sukumar, C.H. van Gils, T. van Laar, E. van der Wall, M. Vooijs, and P.J. van Diest Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer Ann. Oncol. 19 2008 1870 1874
120. J.S. Prabhu, K. Wahi, A. Korlimarla, M. Correa, S. Manjunath, N. Raman, B.S. Srinath, and T.S. Sridhar The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women Tumour Biol. 33 2012 315 323
121. R. Ben Gacem, M. Hachana, S. Ziadi, K. Amara, F. Ksia, M. Mokni, and M. Trimeche Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients Cancer Epidemiol. 36 2012 190 197
122. L. Wu, F. Wang, R. Xu, S. Zhang, X. Peng, Y. Feng, J. Wang, and C. Lu Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis Breast Cancer Res. Treat. 142 2013 619 627
123. S.N. Vasilatos, G. Broadwater, W.T. Barry, J.C. Baker, S. Lem, E.C. Dietze, G.R. Bean, A.D. Bryson, P.G. Pilie, V. Goldenberg, D. Skaar, C. Paisie, A. Torres-Hernandez, T.L. Grant, L.G. Wilke, C. Ibarra-Drendall, J.H. Ostrander, N.C. D'Amato, C. Zalles, R. Jirtle, V.M. Weaver, and V.L. Seewaldt CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis Cancer Epidemiol. Biomarkers Prev. 18 2009 901 914
124. K. Brennan, M. Garcia-Closas, N. Orr, O. Fletcher, M. Jones, A. Ashworth, A. Swerdlow, H. Thorne, E. Riboli, P. Vineis, M. Dorronsoro, F. Clavel-Chapelon, S. Panico, N.C. Onland-Moret, D. Trichopoulos, R. Kaaks, K.T. Khaw, R. Brown, and J.M. Flanagan Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk Cancer Res. 72 2012 2304 2313
125. E.K. Ng, C.P. Leung, V.Y. Shin, C.L. Wong, E.S. Ma, H.C. Jin, K.M. Chu, and A. Kwong Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients PLoS ONE 6 2011 e22233
126. R. Radpour, Z. Barekati, C. Kohler, Q. Lv, N. Bürki, C. Diesch, J. Bitzer, H. Zheng, S. Schmid, and X.Y. Zhong Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer PLoS ONE 6 2011 e16080
127. M. Chimonidou, A. Tzitzira, A. Strati, G. Sotiropoulou, C. Sfikas, N. Malamos, V. Georgoulias, and E. Lianidou CST6 promoter methylation in circulating cell-free DNA of breast cancer patients Clin. Biochem. 46 2013 235 240
128. J.D. Brooks, P. Cairns, R.E. Shore, C.B. Klein, I. Wirgin, Y. Afanasyeva, and A. Zeleniuch-Jacquotte DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study Cancer Epidemiol. 34 2010 717 723
129. R. Bosviel, S. Garcia, G. Lavediaux, E. Michard, M. Dravers, F. Kwiatkowski, Y.J. Bignon, and D.J. Bernard-Gallon BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls Cancer Epidemiol. 36 2012 e177 e182
130. Z. Xu, S.C. Bolick, L.A. DeRoo, C.R. Weinberg, D.P. Sandler, and J.A. Taylor Epigenome-wide association study of breast cancer using prospectively collected sister study samples J. Natl. Cancer Inst. 105 2013 694 700
131. L.A. Deroo, S.C. Bolick, Z. Xu, D.M. Umbach, D. Shore, C.R. Weinberg, D.P. Sandler, and J.A. Taylor Global DNA methylation and one-carbon metabolism gene polymorphisms and the risk of breast cancer in the Sister Study Carcinogenesis 35 2014 333 338
132. H.C. Wu, L. Delgado-Cruzata, J.D. Flom, M. Perrin, Y. Liao, J.S. Ferris, R.M. Santella, and M.B. Terry Repetitive element DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry Carcinogenesis 33 2012 1946 1952
133. N.C. Hsu, Y.F. Huang, K.K. Yokoyama, P.Y. Chu, F.M. Chen, and M.F. Hou Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer PLoS ONE 8 2013 e56256
134. X. Xu, M.D. Gammon, Y. Zhang, Y.H. Cho, J.G. Wetmur, P.T. Bradshaw, G. Garbowski, H. Hibshoosh, S.L. Teitelbaum, A.I. Neugut, R.M. Santella, and J. Chen Gene promoter methylation is associated with increased mortality among women with breast cancer Breast Cancer Res. Treat. 121 2010 685 692
135. A.Q. van Hoesel, C.J. van de Velde, P.J. Kuppen, G.J. Liefers, H. Putter, Y. Sato, D.A. Elashoff, R.R. Turner, J.M. Shamonki, E.M. de Kruijf, J.G. van Nes, A.E. Giuliano, and D.S. Hoon Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study Breast Cancer Res. Treat. 134 2012 1103 1114
136. T. Swift-Scanlan, R. Vang, A. Blackford, M.J. Fackler, and S. Sukumar Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort Cancer Biol. Ther. 11 2011 853 865
137. D.P. Silver, A.L. Richardson, A.C. Eklund, Z.C. Wang, Z. Szallasi, Q. Li, N. Juul, C.O. Leong, D. Calogrias, A. Buraimoh, A. Fatima, R.S. Gelman, P.D. Ryan, N.M. Tung, A. De Nicolo, S. Ganesan, A. Miron, C. Colin, D.C. Sgroi, L.W. Ellisen, E.P. Winer, and J.E. Garber Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer J. Clin. Oncol. 28 2010 1145 1153
138. E.Y. Gil, U.H. Jo, H. Jeong, Y.M. Whang, O.H. Woo, K.R. Cho, J.H. Seo, A. Kim, E.S. Lee, I. Koh, Y.H. Kim, and K.H. Park Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer Int. J. Oncol. 41 2012 611 620
139. D. Dietrich, M. Krispin, J. Dietrich, A. Fassbender, J. Lewin, N. Harbeck, M. Schmitt, S. Eppenberger-Castori, V. Vuaroqueaux, F. Spyratos, J.A. Foekens, R. Lesche, and J.W. Martens CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients BMC Cancer 10 2010 247
140. M.R. Aure, S.K. Leivonen, T. Fleischer, Q. Zhu, J. Overgaard, J. Alsner, T. Tramm, R. Louhimo, G.I. Alnæs, M. Perälä, F. Busato, N. Touleimat, J. Tost, A.L. Børresen-Dale, S. Hautaniemi, O.G. Troyanskaya, O.C. Lingjærde, K.K. Sahlberg, and V.N. Kristensen Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors Genome Biol. 14 2013 R126
141. L. Bojmar, E. Karlsson, S. Ellegård, H. Olsson, B. Björnsson, O. Hallböök, M. Larsson, O. Stål, and P. Sandström The role of microRNA-200 in progression of human colorectal and breast cancer PLoS ONE 8 2013 e84815
142. C. Eichelser, D. Flesch-Janys, J. Chang-Claude, K. Pantel, and H. Schwarzenbach Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression Clin. Chem. 59 2013 1489 1496
143. H.M. Heneghan, N. Miller, A.J. Lowery, K.J. Sweeney, J. Newell, and M.J. Kerin Circulating microRNAs as novel minimally invasive biomarkers for breast cancer Ann. Surg. 251 2010 499 505
144. A. Markou, G.M. Yousef, E. Stathopoulos, V. Georgoulias, and E. Lianidou Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up Clin. Chem. 60 2014 197 205
145. P. Gasparini, L. Cascione, M. Fassan, F. Lovat, G. Guler, S. Balci, C. Irkkan, C. Morrison, C.M. Croce, C.L. Shapiro, and K. Huebner MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers Oncotarget 5 2014 1174 1184
146. Y. Yang, J. Qian, Y. Chen, and Y. Pan Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis Tumour Biol. 2014 10.1007/s13277-014-1846-8
147. A.C. Godfrey, Z. Xu, C.R. Weinberg, R.C. Getts, P.A. Wade, L.A. Deroo, D.P. Sandler, and J.A. Taylor Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort Breast Cancer Res. 15 2013 R42
148. U. Lehmann, B. Hasemeier, M. Christgen, M. Müller, D. Römermann, F. Länger, and H. Kreipe Epigenetic inactivation of microRNA gene hsa-miR-9-1 in human breast cancer J. Pathol. 214 2008 17 24
149. C.S. Wilhelm, K.T. Kelsey, R. Butler, S. Plaza, L. Gagne, M.S. Zens, A.S. Andrew, S. Morris, H.H. Nelson, A.R. Schned, M.R. Karagas, and C.J. Marsit Implications of LINE1 methylation for bladder cancer risk in women Clin. Cancer Res. 16 2010 1682 1689
150. D.C. Koestler, M. Avissar-Whiting, E.A. Houseman, M.R. Karagas, and C.J. Marsit Differential DNA methylation in umbilical cord blood of infants exposed to low levels of arsenic in utero Environ. Health Perspect. 121 2013 971 977
151. T.Y. Yang, L.I. Hsu, A.W. Chiu, Y.S. Pu, S.H. Wang, Y.T. Liao, M.M. Wu, Y.H. Wang, C.H. Chang, T.C. Lee, and C.J. Chen Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure Environ. Res. 128 2014 57 63
152. C.S. Wilhelm-Benartzi, D.C. Koestler, E.A. Houseman, B.C. Christensen, J.K. Wiencke, A.R. Schned, M.R. Karagas, K.T. Kelsey, and C.J. Marsit DNA methylation profiles delineate etiologic heterogeneity and clinically important subgroups of bladder cancer Carcinogenesis 31 2010 1972 1976
153. I. Renard, S. Joniau, B. van Cleynenbreugel, C. Collette, C. Naômé, I. Vlassenbroeck, H. Nicolas, J. de Leval, J. Straub, W. Van Criekinge, W. Hamida, M. Hellel, A. Thomas, L. de Leval, K. Bierau, and D. Waltregny Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples Eur. Urol. 58 2010 96 104
154. M.R. Abern, R. Owusu, and B.A. Inman Clinical performance and utility of a DNA methylation urine test for bladder cancer Urol. Oncol. 32 2014 51.e21 51.e26
155. R. García-Baquero, P. Puerta, M. Beltran, M. Alvarez, R. Sacristan, J.L. Alvarez-Ossorio, and M. Sánchez-Carbayo Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study J. Urol. 190 2013 723 730
156. J. Baden, S. Adams, T. Astacio, J. Jones, J. Markiewicz, J. Painter, C. Trust, Y. Wang, and G. Green Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay J. Urol. 186 2011 2101 2106
157. G.D. Stewart, L. Van Neste, P. Delvenne, P. Delrée, A. Delga, S.A. McNeill, M. O'Donnell, J. Clark, W. Van Criekinge, J. Bigley, and D.J. Harrison Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study J. Urol. 189 2013 1110 1116
158. T. Vener, C. Derecho, J. Baden, H. Wang, Y. Rajpurohit, J. Skelton, J. Mehrotra, S. Varde, D. Chowdary, W. Stallings, B. Leibovich, H. Robin, A. Pelzer, G. Schäfer, M. Auprich, S. Mannweiler, P. Amersdorfer, and A. Mazumder Development of a multiplexed urine assay for prostate cancer diagnosis Clin. Chem. 54 2008 874 882
159. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, V. Vanaclocha, S.B. Baylin, and J.G. Herman Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N. Engl. J. Med. 343 2000 1350 1354
160. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, J.E. Bromberg, P. Hau, R.O. Mirimanoff, J.G. Cairncross, R.C. Janzer, and R. Stupp MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 352 2005 997 1003
161. G. Minniti, M. Salvati, A. Arcella, F. Buttarelli, A. D'Elia, G. Lanzetta, V. Esposito, S. Scarpino, R. Maurizi Enrici, and F. Giangaspero Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide J. Neurooncol. 102 2011 311 316